Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)

The TANGENT study has demonstrated that emactuzumab, a targeted CSF-1R inhibitor, meets its primary and secondary endpoints with high statistical significance in treating Tenosynovial Giant Cell Tumor (TGCT). This pivotal Phase 3 trial showed rapid and durable improvements in tumor response rates, as measured by Objective Response Rate (ORR) and Tumor Volume Score (TVS), alongside significant enhancements in patient-reported outcomes such as PROMIS-PF. Patients receiving emactuzumab experienced these benefits after a short course of treatment, receiving five doses over an eight-week period, which highlights its potential to alleviate the chronic treatment burden associated with existing therapies.

The results underscore the therapeutic potential of emactuzumab as a next-generation treatment option for TGCT, a disease characterized by debilitating joint pain and dysfunction. The short-course regimen not only achieved clinically meaningful outcomes but also maintained a manageable safety profile, consistent with previous clinical experiences. This is particularly relevant in a patient population that often faces the limitations of long-term treatment regimens, which can lead to significant morbidity and reduced quality of life. The rapid onset of action and sustained benefits position emactuzumab as a promising alternative to chronic therapies, addressing critical gaps in current treatment paradigms.

The implications of the TANGENT study extend to the broader landscape of drug development for chronic conditions. With a Biologics License Application (BLA) submission planned for the second half of 2026, the findings from this study could accelerate the pace of innovation in targeted therapies for TGCT and similar conditions. By demonstrating that a short-course treatment can yield significant functional improvements without the need for ongoing therapy, this study may shift the focus of future research towards developing more effective, less burdensome treatment strategies for chronic diseases.

Source: globenewswire.com